MajorAcetylcholinesterase inhibitor with allosteric nicotinic modulation×Acetyl- and butyrylcholinesterase inhibitor
Updated · Methodology
Mechanism
Galantamine is a selective, competitive and reversible inhibitor of acetylcholinesterase and also strengthens the intrinsic action of acetylcholine on nicotinic receptors (galantamine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase and slows the breakdown of acetylcholine released by cholinergic neurons (rivastigmine SmPC, European Medicines Agency, EMA, section 5.1). Both drugs are cholinomimetics. Because of its mechanism of action, galantamine should not be given with other cholinomimetics, including rivastigmine (galantamine SmPC, AEMPS, section 4.5). Rivastigmine should not be given with them either, because of its pharmacodynamics and possible additive effects (rivastigmine SmPC, EMA, section 4.5). The documents describe no pharmacokinetic interaction for this pair: according to the rivastigmine SmPC, metabolic interactions are unlikely (EMA, section 4.5), and galantamine has a low likelihood of clinically relevant pharmacokinetic interactions (galantamine SmPC, AEMPS, section 4.5).
Symptoms
The documents do not describe how this particular combination presents: the two drugs are not given together in the first place because of their shared mechanism and possible additive effects (galantamine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and rivastigmine SmPC, European Medicines Agency, EMA, section 4.5). Both drugs can slow the heart rate. Through vagal effects, galantamine can cause bradycardia and any type of atrioventricular node block. QTc prolongation at therapeutic doses and torsade de pointes in overdose have been reported with galantamine (galantamine SmPC, AEMPS, section 4.4). Rivastigmine can prolong the QT interval and cause bradycardia, a risk factor for torsade de pointes (rivastigmine SmPC, EMA, section 4.4). The overdose section of the rivastigmine SmPC shows what cholinergic toxicity looks like: miosis, flushing, abdominal pain, nausea, vomiting, diarrhoea, slow heart rate, bronchospasm and increased bronchial secretions, heavy sweating, involuntary urination or defecation, lacrimation, low blood pressure and excess salivation. More severe cases bring muscle weakness, fasciculations, seizures and respiratory arrest, which may be fatal (rivastigmine SmPC, EMA, section 4.9).
Management
Avoid the combination. Galantamine should not be given with other cholinomimetics, and rivastigmine is named among them (galantamine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Because of possible additive effects, rivastigmine should not be given with other cholinomimetics either (rivastigmine SmPC, European Medicines Agency, EMA, section 4.5). The US label for the rivastigmine patch does not recommend such combinations unless they are clinically necessary (rivastigmine label, US Food and Drug Administration, FDA, section 7.2). The contraindication sections of these documents do not list the pair. The documents give no interval for switching from one drug to the other. The plasma half-life of rivastigmine is about 1 hour for the capsules and about 3.4 hours for the patch, while acetylcholinesterase inhibition lasts about 9 hours (rivastigmine SmPCs, EMA, section 4.9). If rivastigmine has been interrupted for more than three days, restart it at the starting dose, 1.5 mg twice a day for the capsules or the 4.6 mg/24 h patch (rivastigmine SmPCs, EMA, section 4.2). Galantamine is started at 8 mg a day for 4 weeks (galantamine SmPC, AEMPS, section 4.2). If signs of cholinergic toxicity appear, manage them as an overdose and treat the symptoms. In massive rivastigmine overdose, intravenous atropine can be used, starting at 0.03 mg/kg, and the SmPC does not recommend scopolamine as an antidote (rivastigmine SmPC, EMA, section 4.9). According to the galantamine SmPC, the starting dose of atropine in severe cases is 0.5–1.0 mg intravenously (AEMPS, section 4.9).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Galantamina, Reminyl 16 mg cápsulas duras de liberación prolongada (nº registro 66651), sección 4.5 (2026)– AEMPS, CIMA, nº registro 66651 (Reminyl 16 mg cápsulas duras de liberación prolongada, Essential Pharma), revisión 09/2026, secciones 4.2, 4.4, 4.5, 4.9 y 5.1
- FDA: Galantamine tablets (Upsher-Smith) prescribing information (2024)– FDA, DailyMed setid 10497273-d907-0514-e063-6294a90a1362 (Upsher-Smith Laboratories), versión 8, revisión 11/2024, secciones 4, 5.3 y 7.2
- EMA: Ficha técnica: Rivastigmina – Exelon cápsulas duras (EU/1/98/066), sección 4.5 (2026)– EMA, SmPC Exelon 1,5 mg cápsulas duras (EU/1/98/066, Novartis Europharm), texto en CIMA nº 98066002, consultado 25.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.4, 4.5, 4.9 y 5.1
- EMA: Ficha técnica: Rivastigmina – Exelon parche transdérmico (EU/1/98/066), sección 4.2 (2026)– EMA, SmPC Exelon 13,3 mg/24 h parche transdérmico (EU/1/98/066, Novartis Europharm), texto en CIMA nº 198066029, consultado 25.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.5 y 4.9
- FDA: Exelon Patch (rivastigmine transdermal system) prescribing information (2020)– FDA, DailyMed setid 07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0 (Novartis Pharmaceuticals), versión 30, revisión 06/2020, secciones 4 y 7.2